Draft:Maqbool A. Halepota, MD, FACP, CPE

• Comment: This is purely promotional and confuses Wikipedia with LinkedIn. Drmies (talk) 02:17, 29 March 2025 (UTC)

---

Maqbool A. Halepota, MD, FACP, CPE

Maqbool Alam Halepota, MD, FACP, CPE, is a board-certified oncologist and hematologist, human rights advocate, and author. He is a managing partner and serves as the medical director of Palo Verde Cancer Specialists in Scottsdale, Arizona, one of five locations in the Metro Phoenix area. Dr. Halepota is also a member of the Board of Directors of Valley Integrated Alliance of Specialists, Arizona (VIAS-AZ), and GMS Biotech. He serves as the medical oncology specialty representative on the Medicare Carrier Advisory Committee for the state of Arizona.

Dr. Halepota currently serves as president of the Sindi Association of North America (SANA), is the founding president of the Sindhi American Political Action Committee, and is chairman of the board of directors of Sindhi Foundation. Dr. Halepota is also a founding member of the Fund for Educational Development in Sindh and has served as member of the board of directors for the American Civil Liberties Union in Arizona.

Early Life and Education

Maqbool A. Halepota was born in the historical city of Hyderabad, Pakistan, the former capital of Sindh, on the banks of the Indus River. He received a Bachelor of Medicine and Bachelor of Surgery from Sindh Medical College in Karachi, Pakistan; completed an internship and residency at Jinnah Postgraduate Medical Center in Karachi, Pakistan; completed an internship in the Department of Internal Medicine at the Cornell University-affiliated Methodist Hospital in Brooklyn, New York; and completed a residency in the Department of Internal Medicine at the University of Kentucky Medical Center in Lexington, Kentucky.

Dr. Halepota practiced internal medicine in Berea, Kentucky for four years, serving an indigent population in one of the poorest counties in the state. In recognition of his service, Governor Paul E. Patton in 1999 commissioned Dr. Halepota into the Honorable Order of Kentucky Colonels, the highest honor bestowed by the governor of the state of Kentucky on individuals for their noteworthy accomplishments and exemplary service to the community, state, and nation. After that, he completed a fellowship in hematology and oncology at the University of Kentucky.

Career

From July 1996 through June 1999, Dr. Halepota served as attending physician at The White House Clinic in Berea, Kentucky, where he served on multiple committees including Medical Executive, Utilization Review, Long-Term, and Special Care. He served as chairperson of the Medical/Surgical Floors Committee, where he was instrumental in developing clinical pathways. He also developed and established protocols for quality control and corporate compliance.

In July 1999, Dr. Halepota established Hamburg Medical Associates in Lexington, Kentucky, where he served as attending physician and CEO. The practice provided medical care and coverage to nursing homes in the area.

Following the completion of his fellowship in hematology and oncology at the University of Kentucky in 2003, Dr. Halepota moved to Phoenix, Arizona to join Palo Verde Cancer Specialists (PVCS), where he is a managing partner and currently serves as the medical director of PVCS in Scottsdale, Arizona. He also served as medical director of Ridgecrest Healthcare Skilled Nursing Facility in Phoenix, Arizona from 2005 to 2006.

He is Board Certified in Internal Medicine and Oncology, received a Fellowship in the American College of Physicians (FACP) in 2004, and acquired his Certification as a Physician Executive (CPE) – Certifying Commission in Medical Management (CCMM) in 2017. Other certifications include Diplomate (Board-Certified) – American Board of Medical Oncology; Diplomate (Board-Certified) – American Board of Internal Medicine; Board-Eligible – American Board of Hematology; Advanced Trauma Life Support; Federal Licensing Examination; and Foreign Mediccal Graduate Examination in the Medical Sciences. He is licensed to practice medicine in Arizona, California, Florida, Georgia, Kentucky, New York, and Texas in the United States; as well as in Pakistan.

Dr. Halepota has been recognized as a "Top Oncologist" on multiple occasions by independent ranking organizations, both in Arizona and nationally.

Memberships

• Member, American Society of Clinical Oncology
• Member, American Society of Hematology
• Member, American College of Physician Executives
• Member, International Association for the Study of Lung Cancer
• Member, American Association of Naturopathic Physicians
• Member - Speaker Bureau, Novartis Pharmaceuticals
• Member - Speaker Bureau, Lilly Oncology Pharmaceuticals
• Member - Speak Bureau, Celgene Pharmaceuticals
• Member - Board of Directors, GMS Biotech
• Member - Board of Directors, Community Oncology Alliance
• Member - Board of Directors, Valley Integrated Alliance of Specialists, PLLC (VIASAZ)
• Founding President - Board of Directors, Palo Verde Cancer Center, Scottsdale
• Chair - Finance Committee, Association of Death Education and Counseling
• Medical Oncology Specialty Representative, Medicare - Arizona Carrier Advisory Committee
  

He previously served as a member of the board of directors of the Community Oncology Alliance, chaired multiple committees including the Department of Medicine at Paradise Valley Hospital, Lung and Head/Neck Cancer and Data Safety at Virginia Piper Cancer Center, and Pharmacy and Therapeutics at Scottsdale Healthcare. Dr. Halepota also served as a member of the Medical Executive Committee at both Paradise Valley Hospital and Virginia Piper Cancer Center.

Associations, Organizations, and Affiliations

Dr. Halepota is highly respected and well-known among the Sindhi communities in the US, Canada, and all over Sindh for his non-partisan advocacy and philanthropy on behalf of the most oppressed sections of the society.

He currently serves as the elected president of the Sindhi Association of North America (SANA), and has previously served as the organization's general secretary. He is the founding president of Sindhi American Political Action Committee (SAPAC), a founding member of the Fund for Educational Development in Sindh, chairman of the board of directors for the Sindhi Foundation, and previous member of the board of directors for the ACLU in Arizona.

Bibliography / Publications

Dr. Halepota's work has been published in peer-reviewed medical journals and online magazines. In 2024, he published his first book, Sindhis in Global Context: Past, Present, Future, and Origins (2600 BCE to ...) to document the rich history and culture of Sindhi people and bring awareness to the issues that Sindhis face.

Publications/Peer-Reviewed Manuscripts:

• M. Halepota, M. Mohiuddin, P. Desimone, MM Ahmed. "Durable Local Responses with Subtherapeutic Doses of Concurrent Radiation and Gemcitabine in a Patient with Refractory Hodgkin's Disease." Clinical Advances in Hematology & Oncology, 7/2003;1(7):413-5.
• Glen J. Weiss, Arlet Alarcon, Maqbool Halepota, Robert J. Penny, Daniel D. Von Hoff. "Molecular Characterization of Interdigitating Dendritic Cell Sarcoma." Rare Tumors, 2010;2:e50.
• Zartaj Ahmed, Ramesh K. Ramanathan, Sunil Ram, James Newell, Maqbool Halepota. "Unusual Relapse of Primary Central Nervous System Lymphoma at Site of Lumbar Puncture." Case Reports in Hematology, Vol. 2014, Article ID 161952, 4 pages.

Manuscripts in Preparation:

• "A Meta-Analysis of the Efficacy of Cisplatin vs. Carboplatin in the Treatment of Esophageal Cancer."

Articles:

• Bence, A.K., Anderson, E.B., Halepota, M.A. et al. "Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects." Invest New Drugs 23, 39–49 (2005). https://doi.org/10.1023/B:DRUG.0000047104.45929.ea.
• Miller, Mary E. DO*; Coates, Alison M. BS†; Halepota, Maqbool A. MD‡; Kovalsky, Eric R. MD†; Passalaqua, Susan MD†; Gotway, Michael B. MD†; Korn, Ronald L. MD, PhD†§. Giant Cell Cancer of the Lung: Diagnosis and Treatment Monitoring With PET/CT. Clinical Pulmonary Medicine 17(2):p 106-108, March 2010. | DOI: 10.1097/CPM.0b013e3181d139ab.

Abstracts:

• Maqbool Halepota, Mohammed Mohuiddin, Philip DeSimone. "Use of Low Dose Gemcitabine with Concurrent Radiation Therapy in Refractory Hodgkin's Disease." Blood, 2001;98(11):242b.

Posters:

• Val R. Adams, Aimee K. Bence, Eric B. Anderson, Maqbool A. Halepota, Deborah A. Smith, Kevin M. Koch, Carolyn J. Bowen, Steve G. Mangum, Neil L. Spector, George A. Davis, Michael A. Doukas, Philip A. DeSimone. "A phase I pharmacokinetic-pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects." Proc Am Soc Clin Oncol (2002) 21:94a (abstract 374). ASCO Thirty-Eighth Annual Meeting, Orlando, FL, May 21, 2002.
• Philip A. DeSimone, Aimee K. Bence, Eric B. Anderson, Maqbool A. Halepota, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve G. Mangum, Neil L. Sepctor, George A. Davis, Michael A. Doukas, Val R. Adams. "A phase I study to investigate the safety, tolerability, and pharmacokietics of single oral escalating doses of GW572016 in healthy volunteers." Proc Am Soc Clin Oncol (2002) 21:94a (abstract 375). ASCO Thirty-Eighth Annual Meeting, Orlando, FL, May 21, 2002.

Research Experience:

• 06/01–08/01: Co-Investigator — "A Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral GW572016 Doses in Healthy Subjects."
• 05/01: Co-Investigator — "A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ICA-17043 in Patients with Sickle Cell Disease Who Are in the Steady, Non-Crisis State."
• 01/01–03/01: Co-Investigator — "A Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GW572016 Ditosylate Monohydrate in Healthy Volunteers."

Appearances

Dr. Halepota has given numerous talks and presentations, including:

• "Doctors with Borders: Embracing the Potential of Immigrant Doctors." CATO Institute, 2020.
• "Coming to the Rescue: How International Medical Graduates Can Increase Access to Healthcase." CATO Institute, 2024.
• "Is Advocating Health Care Licensing Reform About to Go Mainstream?" CATO Institute, 2020.
• "Demystifying the 'D' Word: Patients, Providers, and Caregivers." Association for Death Education and Counseling, 2021.

References

[[:Category:People]]